Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03913130
Other study ID # PQ-110-002
Secondary ID 2018-003500-40
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date May 13, 2019
Est. completion date October 3, 2022

Study information

Verified date December 2022
Source ProQR Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.


Description:

Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Subjects will be given the opportunity to enroll into this extension study for continued dosing if available data support current and/or future benefits for the subject. The Investigator, in consultation and agreement with the Medical Monitor, will decide on enrollment of each individual subject, as well as on dosing of the first treated eye and treatment initiation of the contralateral eye. Continued subject treatment in this study is desirable, but cannot be guaranteed, since it will depend on the risks and benefit of further treatment on a case-by-case basis, as discussed and agreed upon with the Medical Monitor. The contralateral eye and the first treated eye will be injected 3 months apart. The injection interval of 3 months between both eyes will limit burden for the subjects, with a 3 month-visit frequency during the course of the study. This between-eye interval could be adapted if safety data are supportive, and for logistic reasons, and in agreement with the Medical Monitor. The same safety monitoring protocol and efficacy assessments will apply to both eyes. QR-110 will be administered via intravitreal (IVT) injection.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date October 3, 2022
Est. primary completion date October 3, 2022
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor - Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT. - Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator. - An adult (= 18 years) willing and able to provide informed consent for participation OR a minor (6 to < 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation. - Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol. Exclusion Criteria: - Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014). - Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor. - Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor. - Pregnant or breast-feeding female.

Study Design


Intervention

Drug:
QR-110
First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration

Locations

Country Name City State
Belgium Ghent University Hospital and Ghent University Ghent
United States University of Iowa Iowa City Iowa
United States Scheie Eye Institute, University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
ProQR Therapeutics

Countries where clinical trial is conducted

United States,  Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Ocular AEs Frequency of ocular adverse events (AEs) 24 months
Primary Frequency of Non-ocular AEs Frequency of non-ocular AEs 24 months
Secondary Change in BCVA in First Treated Eye Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye 24 months
Secondary Change in Mobility Course Score Change in Mobility course score 24 months
Secondary Change in Photoreceptor Outer Segment Layer Thickness Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT) 24 months
Secondary Change in OCI Change in Oculomotor Instability (OCI) 24 months
Secondary Change in FST Blue Change in Full-Field Stimulus Testing (FST) - blue stimuli 24 months
Secondary Change in FST Red Change in Full-Field Stimulus Testing (FST) - red stimuli 24 months
Secondary Change in VFQ-25 Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects) 24 months
Secondary Change in CVAQ Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects) 24 months
Secondary Change in PLR Change in Pupillary Light Reflex (PLR) (latency and amplitude) 24 months
Secondary Change in NIRAF Change in Near Infrared AutoFluorescence (NIRAF) 24 months
Secondary Change in BCVA in Treated Contralateral Eye Change in Best Corrected Visual Acuity (BCVA) in Treated Contralateral Eye 24 months
Secondary Change in BCVA in Non-Treated Contralateral Eye Change in Best Corrected Visual Acuity (BCVA) in Non-Treated Contralateral Eye 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Completed NCT02811692 - Study for Collection of Aflibercept Data in Routine Practice
Recruiting NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Phase 3
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT04799704 - Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
Recruiting NCT05876689 - Swept Source OCT Imaging With the DREAM VG-OCT
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2
Recruiting NCT04150432 - Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children N/A
Not yet recruiting NCT05550740 - Repeated Low-Level Red-Light Therapy for Shortening Axial Length N/A
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1
Completed NCT00333203 - Next Generation Ophthalmic Irrigating Solution Posterior Segment Study Phase 3
Not yet recruiting NCT05565547 - Multimodal Equipment for Teleophthalmology Assessment (META)
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Completed NCT05211089 - Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
Not yet recruiting NCT06070467 - Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases

External Links